MedPath

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Registration Number
NCT04448431
Lead Sponsor
H. Lundbeck A/S
Brief Summary

The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit

Detailed Description

The study will consist of a screening period of up to 14 days before the Baseline Visit, followed by an 8-week Treatment Period with vortioxetine or desvenlafaxine. A Safety Follow-up Visit will be performed approximately 4 weeks after the Primary Outcome/Withdrawal Visit.

At Baseline, patients will be equally randomised (1:1) to 1 of the 2 treatment groups for an 8-week, double-blind Treatment Period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
605
Inclusion Criteria
  • The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a MADRS total score ≥24 at screening and baseline.
  • The patient has had the current MDE for ≥3 months and < 12 months.
  • The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.
  • The patient wants to switch antidepressant treatment.
Exclusion Criteria
  • The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.

Other in- and exclusion criteria may apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DesvenlafaxineDesvenlafaxine8 weeks treatment
VortioxetineVortioxetine8 weeks treatment
Primary Outcome Measures
NameTimeMethod
Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total scoreFrom baseline to Week 8

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

Secondary Outcome Measures
NameTimeMethod
Remission (defined as a MADRS total score =<10)At Week 8

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

Change in Digital Symbol Substitution Test (DSST) total scoreFrom baseline to Week 8

DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning).

Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total scoreFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Change in Q-LES-Q work subscaleFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Change in Q-LES-Q school/course subscaleFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Change in Q-LES-Q leisure time activities subscaleFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Change in MADRS anhedonia factor scoreFrom baseline to Week 8

(based on items 1(apparent sadness),2 (reported sadness),6 (concentration difficulties),7 (lassitude),8 (inability to feel))

Clinical Global Impression Scale- Global Improvement (CGI-I) scoreat Day 7,28,56

The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse)

Response (defined as a => 50% decrease from baseline in MADRS total score)At Week 8

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)From baseline to Week 8

The EEfRT is a computerized task which measures reward motivation in which participants are presented with a series of repeated trials during which they choose between performing a ''hard-task'' or an ''easy-task'' in order to earn varying amounts of monetary rewards.

Change in Clinical Global Impression - Severity of Illness (CGI-S) scorefrom baseline to Week 8

The CGI-S scale measures the severity of psychiatric symptoms on a 7-point scale from 1-7. The scores indicated the following: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The score ranged from 1-7, where 1 indicated absence of symptoms and higher score indicated greater severity of symptoms.

Change in Functioning Assessment Short Test (FAST) total scoreFrom baseline to Week 8

The FAST is a valid and reliable instrument, easy to apply which requires a short period of time to administer. Evaluates functioning taking into account the last 15 days. It was developed for the clinical evaluation of the main difficulties presented by psychiatric patients, and has been validated in several languages for patients with bipolar disorder. The FAST scale consists of 24 items which allow the assessment of six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time

Change in FAST sub-domain scoresFrom baseline to Week 8

The FAST is a clinician-rated scale designed to assess difficulty in functioning. The FAST consists of 24 items in 6 specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, leisure time. Each item is rated on a 4-point scale from 0 (no difficulty) to 3 (severe difficulty). The items are summed to yield a total score ranging from 0 to 72 with higher scores reflecting more serious difficulties.

Change in Q-LES-Q household duties subscaleFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Change in Q-LES-Q social relations subscaleFrom baseline to Week 8

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Trial Locations

Locations (80)

INAPsi (Instituto Nacional de Psicopatologia)

🇦🇷

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

CRI Centro Regiomontano de Investigacion SC

🇲🇽

Monterrey, Nuevo Leon, Mexico

Leningrad Regional Psychoneurological Dispensary

🇷🇺

Roshchino, Leningrad Region, Russian Federation

Yaroslavl Regional Clinical Psychiatry Hospital

🇷🇺

Yaroslavl, Russian Federation

MC Complete Medical Solutions

🇧🇬

Samokov, Bulgaria

Health Pharma Professional Research S.A. de C.V.

🇲🇽

Ciudad de Mexico, Mexico

SI INPN Namsu

🇺🇦

Kharkiv, Ukraine

LLC Astarta

🇷🇺

Saint-Petersburg, Russian Federation

Epamed, S.R.O

🇸🇰

Kosice, Slovakia

Psycholine S.R.O.

🇸🇰

Rimavska Sobota, Slovakia

Communal Non-Commercial Enterprise of Kharkiv Regional Council Regional clinical psychiatric hosp...

🇺🇦

Kharkiv, Kharkivska, Ukraine

Crystal Comfort, s.r.o.

🇸🇰

Vranov Nad Topou, Slovakia

Psychiatricka Ambulancia

🇸🇰

Zlate Moravce, Slovakia

BONA MEDIC s.r.o.

🇸🇰

Zlate Moravce, Slovakia

ONE LIFETIME Lakarmottagning

🇸🇪

Skövde, Sweden

Clinica Privada Banfield

🇦🇷

Banfield, Buenos Aires, Argentina

Cenydet-Centro Neurobiologico Y De Estres Traumatico-Biopsychomedical Research Group Srl

🇦🇷

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Fundacion para el Estudio y Tratamiento de las enfermedades mentales FETEM

🇦🇷

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Clinica Privada De Salud Mental Santa Teresa De Avila

🇦🇷

La Plata, Buenos Aires, Argentina

Sanatorio Prof. Leon S. Morra S.A.

🇦🇷

Cordoba, Providencia De Cordo, Argentina

Instituto De Neurociencias San Agustin SA

🇦🇷

La Plata, Buenos Aires, Argentina

CIAP (Centro de Investigacion y Asistencia en Psiquiatria)

🇦🇷

Rosario, Santa Fe, Argentina

CINME (Centro de Investigaciones Metabolicas de Buenos Aires)

🇦🇷

Ciudad Autonoma De Buenos Aires, Argentina

CEN (Centro Especializado Neurociencias)

🇦🇷

Cordoba, Argentina

Instituto Medico DAMIC - Fundacion Rusculleda

🇦🇷

Cordoba, Argentina

Instituto Modelo de Neurologia Fundacion Lennox

🇦🇷

Cordoba, Argentina

Centro De Asistencia E Investigacion En Neurociencias CENAIN

🇦🇷

Mendoza, Argentina

Resolution Psicopharmacology Research Institute

🇦🇷

Mendoza, Argentina

Algemeen Ziekenhuis St. Lucas-St. Jozef

🇧🇪

Brugge, Belgium

SINAPS - University Antwerpe- Psychiatrisch Ziekenhuis Duffel

🇧🇪

Duffel, Belgium

Cliniques De Mont-Godinne

🇧🇪

Yvoir, Belgium

MHAT Dr. Hristo Stambolski

🇧🇬

Kazanlak, Bulgaria

UMHAT Sv. Ivan Rilski EAD

🇧🇬

Plovdiv, Bulgaria

Center For Mental Health-Rousse

🇧🇬

Rousse, Bulgaria

Centre for Mental Health- Sofia

🇧🇬

Sofia, Bulgaria

Diagnostic Consultative Center Mladost-M Varna OOD

🇧🇬

Varna, Bulgaria

Clinline services s.r.o.

🇨🇿

Hostivice, Czechia

Meditrine s.r.o. - Psychiatricka Ambulance, Lecebne Centrum

🇨🇿

Havirov, Czechia

Clintrial s.r.o.

🇨🇿

Prague, Prague 10, Czechia

Dr.Jan Holan MD, Office of

🇨🇿

Brno, Czechia

Neuropsychiatrie HK, s.r.o.

🇨🇿

Hradec Kralove, Czechia

National Institute of Mental Health

🇨🇿

Klecany, Czechia

Psychiatricka Ambulance

🇨🇿

Kutna Hora, Czechia

A-Shine s.r.o.

🇨🇿

Plzen, Czechia

Institut neuropsychiatricke pece

🇨🇿

Praha 8, Czechia

Psihiatrijas Centrs

🇱🇻

Liepaja, Liepajas Rajons, Latvia

Medical Care and Research S.A. de C.V.

🇲🇽

Merida, Yucatan, Mexico

Marienthali Kliinik

🇪🇪

Tallinn, Estonia

Riga Centre Of Psychiatry And Addiction Disorders

🇱🇻

Riga, Latvia

Sigulda Hospital Outpatient Clinic

🇱🇻

Sigulda, Latvia

GUZ Engels Psychiatric Hospital

🇷🇺

Engels, Russian Federation

Region Specialized Psychiatric Hospital No.2

🇷🇺

Stavropol Region, Kochubeev District, Russian Federation

Arkhangelsk Regional Clinical Mental Hospital

🇷🇺

Arkhangelsk, Russian Federation

Moscow Scientific Research Institute of Psychiatry

🇷🇺

Moscow, Russian Federation

Clinic named after professor Yu. N. Kasatkin FGBOU DPO RMANPO Minzdrava Rossii

🇷🇺

Moscow, Russian Federation

Nizhny Novgorod Region State Institution Of Healthcare Clinical Psychiatric Hospital 1 Of Nizhny ...

🇷🇺

Nizhny Novgorod, Russian Federation

Rostov State Medical University of the Minzdravsotsrazvitiya of Russia

🇷🇺

Rostov-on-Don, Russian Federation

LLC Medical Center Nova Vita

🇷🇺

Rostov-on-Don, Russian Federation

Hospital OrKli , LLC

🇷🇺

Saint-Petersburg, Russian Federation

Saratov State Medical University

🇷🇺

Saratov, Russian Federation

State Budgetery Educational Institution Of Higher Professional Education Smolensk State Medical U...

🇷🇺

Smolensk, Russian Federation

St. Nicolas State Psychiatric Hospital

🇷🇺

St. Petersburg, Russian Federation

Psychiatricka ambulancia, MENTUM, s.r.o.

🇸🇰

Bratislava, Slovakia

Centro De Salud Mental La Corredoria

🇪🇸

Oviedo, Asturias, Spain

Hospital Universitario Fundacion Alcorcon

🇪🇸

Alcorcon, Madrid, Spain

Hospital De La Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Hospital Psiquiatric de Palma de Mallorca

🇪🇸

Palma de Mallorca, Spain

Smaert & Psykiatricentrum Malmoe

🇸🇪

Malmo, Skane, Sweden

Affecta Psyikiatri AB

🇸🇪

Halmstad, Sweden

ProbarE i Lund

🇸🇪

Lund, Sweden

Communal Non-commercial Enterprise Cherkasy regional psychiatric hospital of Cherkasy regional co...

🇺🇦

Smila, Cherkasy, Ukraine

Municipal Non-profit Enterprise Odesa Regional Psychiatric Hospital No.2 of Odesa Regional Council

🇺🇦

Kominternivskyy, Odesa, Ukraine

ProbarE

🇸🇪

Stockholm, Sweden

Ivano-Frankivsk Oblast neuropsychiatric hospital No. 3

🇺🇦

Ivano-Frankivsk, Ukraine

Academy of Medical Sciences of Ukraine - Institute of Neurology, Psychiatry and Narcology

🇺🇦

Kharkiv, Ukraine

CI of KRC Regional psychiatric and narcological medical association

🇺🇦

Glevakha, Ukraine

Lviv Regional State Clinical Psychiatric Hospital, Lviv Danylo Galytsky National Medical University

🇺🇦

Lviv, Ukraine

Odessa Regional Medical Centre of Mental Health

🇺🇦

Odessa, Ukraine

Ukrainian Medical Stomatological Academy, Chair Of Psychiatry, Narcology And Medical Psychology B...

🇺🇦

Poltava, Ukraine

Vinnitsa National Medical University

🇺🇦

Vinnitsa, Ukraine

© Copyright 2025. All Rights Reserved by MedPath